source
- Mark Cuban’s Cost Plus Drugs plans to enter custom rare-disease drug marketMark Cuban says his company Cost Plus Drugs will expand beyond generic medicines into the custom‑made rare disease space. The firm, which currently buys generic drugs and sells them directly to con…
- Roivant reports Lisraya beats placebo in Phase 3 trials for non-infectious uveitisRoivant and its spinout Priovant announced that Lisraya, an immune-modifying oral drug, showed statistically significant benefit over placebo in two Phase 3 trials for non-infectious uveitis. The…